| Literature DB >> 26287217 |
Randy Chi Fai Cheung1, Tzi Bun Ng2, Jack Ho Wong3, Wai Yee Chan4.
Abstract
Chitosan is a natural polycationic linear polysaccharide derived from chitin. The low solubility of chitosan in neutral and alkaline solution limits its application. Nevertheless, chemical modification into composites or hydrogels brings to it new functional properties for different applications. Chitosans are recognized as versatile biomaterials because of their non-toxicity, low allergenicity, biocompatibility and biodegradability. This review presents the recent research, trends and prospects in chitosan. Some special pharmaceutical and biomedical applications are also highlighted.Entities:
Keywords: biomedical applications; chitosan; pharmaceutical applications
Mesh:
Substances:
Year: 2015 PMID: 26287217 PMCID: PMC4557018 DOI: 10.3390/md13085156
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Scopus indexed publications related to chitosan and its derivatives.
Figure 2A schematic presentation of chitosan preparation from raw materials.
Physiochemical characteristics of chitosan and their methods of determination.
| Physiochemical Characteristics | Method of Determination |
|---|---|
| molecular weight | viscometry; gel permeation chromatography; light scattering; high performance liquid chromatography; matrix-assisted laser desorption/ionization-mass spectrometer |
| degree of deacetylation | infrared spectroscopy; ultra violet spectrophotometry; nuclear magnetic resonance spectroscopy (1H-NMR and 13C-NMR); conductometric titration; potentiometric tiltration; differential scanning calorimetry |
| crystallinity | X-ray diffraction |
The antimicrobial activities of chitosan and its derivatives
| Targets | Chitosan or Its Derivatives/MIC in μg/mL Reference | |
|---|---|---|
| Gram-negative bacteria | chitosan 0.025% [ | |
| chitosan 8 μg/mL [ | ||
| chitosan 8 μg/mL [ | ||
| á-chitosan 9 μg/mL [ | ||
| chitosan 0.0125% [ | ||
| chitosan 0.025% [ | ||
| chitosan 0.05% [ | ||
| chitosan 16 μg/mL [ | ||
| á-chitosan 5 μg/mL [ | ||
| chitosan 16 μg/mL [ | ||
| Gram-negative bacteria | chitosan 0.05% [ | |
| á-chitosan 9 μg/mL [ | ||
| Gram-positive bacteria | chitosan 0.05% [ | |
| chitosan 8 μg/mL [ | ||
| chitosan 0.025% [ | ||
| chitosan 0.025% [ | ||
| chitosan 0.05% [ | ||
| á-chitosan 9 μg/mL [ | ||
| á-chitosan 9 μg/mL [ | ||
| Fungi | chitosan 0.1% [ | |
| chitosan 0.1% [ | ||
| chitosan 5 μg/mL [ | ||
| chitosan 20 μg/mL [ | ||
| chitosan 65 μg/mL [ | ||
| chitosan 57.5 μg/mL [ | ||
| chitosan 2.5 μg/mL [ | ||
| chitosan 2.5 μg/mL [ | ||
| chitosan 1 μg/mL [ | ||
| chitosan 100 μg/mL [ | ||
| chitosan 5 μg/mL [ | ||
| chitosan 2.5 μg/mL [ | ||
| chitosan 12.5 mg/mL [ | ||
| Virus | IC50 of cytopathic effect by HIV-1RF | QMW-chitosan oligomers 48.14 μg/mL [ |
| IC50 of cytopathic effect by HIV-1IIIB | WMQ-chitosan oligomers 48.01 μg/mL [ | |
| IC50 of p24 production by HIV-1IIIB | QMW-chitosan oligomers 67.35 μg/mL [ | |
| IC50 of p24 production by HIV-1Ba-L | WMQ-chitosan oligomers 98.73 μg/mL [ | |
| IC50 of p24 production by HIV-1RTMDR1 | QMW-chitosan oligomers 81.03 μg/mL [ | |
| IC50 of luciferase expression by HIV-1RF | QMW-chitosan oligomers 68.13 μg/mL [ | |
| IC50 of interaction between gp41 and CD4 by HIV-1 | QMW-chitosan oligomers 39.13 μg/mL [ | |
| IC50 of syncytia formation by HIV-1RF | sulfated chitooligosaccharides 2.19 μg/mL [ | |
| EC50 of protection of lytic effect by HIV-1 | sulfated chitooligosaccharides 1.43 μg/mL [ | |
| IC50 of p24 production by HIV-1RF | sulfated chitooligosaccharides 4.33 μg/mL [ | |
| IC50 of p24 production by HIV-1Ba-L | sulfated chitooligosaccharides 7.76 μg/mL [ | |
A summary of antitumor activities of chitosan and its derivatives.
| Compound | Target Cell Lines or | Results | Ref. |
|---|---|---|---|
| chitosan | meth-A solid tumor transplanted into BALB/c mice | increased production of interleukins 1 and 2, sequentially, leading to the manifestation of antitumor effect through proliferation of cytolytic T-lymphocytes with the optimum inhibition ratio at the dose of 10 mg/kg | [ |
| chitosan | aberrant crypt tumor lesions in the colon of mice | elevated lymphokine production and proliferation of cytolytic T-lymphocytes at the dose of 5 mg/kg | [ |
| chitosan | A375, SKMEL28, and RPMI7951 cell lines | chitosan was coated in culture wells in which cultures with A375, SKMEL28, and RPMI7951 cells were carried out. | [ |
| decreased adhesion of A375 cells | |||
| decreased proliferation of SKMEL28 cells | |||
| inhibited specific caspases, upregulated Bax and downregulated Bcl-2 and Bcl-XL in RPMI7951 cells | |||
| induced CD95 receptor expression in RPMI7951 cell surface which renders them more susceptible to FasL-induced apoptosis | |||
| carboxymethyl chitosan | hydrogen peroxide induced apoptosis models of Schwann cells | The cell viability was improved in a dose-dependent manner with maximum effect of 2.02 ± 0.16 fold at the dose of 200 μg/mL carboxymethyl chitosan | [ |
| decreased caspase-3, -9 and Bax activities and increased Bcl-2 activity | |||
| carboxymethyl chitosan | BEL-7402 cell line | reduced the expression of MMP-9 in a dose-dependent manner | [ |
| hepatoma-22 cells in Kunming mice | inhibited the lung metastasis mouse model with the highest inhibition of 66.56% at the dose of 300 mg/kg | ||
| chitosan | PC3 A549 and HepG2 cell line | suppressed cancer cell growth of PC3 A549 and HepG2 cells for 50% cell death at 25 μg/mL, 25 μg/mL and 50 μg/mL, respectively | [ |
| chitosan | HepG2 and LCC cell line | inhibited MMP-9 expression, reduced cells in S-phase and decreased the rate of DNA synthesis, upregulated p21 and downregulated PCNA, cyclin A and CDK-2 with the highest inhibition at the dose of 1 mg/kg | [ |
| HepG2 and LCC xenografts in mouse model | inhibited tumor growth and decreased the number of metastatic colonies at the dose of 500 mg/kg |
Figure 3Scavenging effects of N-CECS with different degrees of substitution toward ABTS radicals. Reprinted with permission from [75] Copyright (2015) American Chemical Society.
Figure 4A diagrammatic presentation of how the chitosan-based wound dressing works.